These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 2585747)

  • 61. Adverse effects of atrial fibrillation and syncope induced by calcium-channel blockers in hypertrophic cardiomyopathy.
    Doiuchi J; Hamada M; Ochi T; Ito T; Kokubu T
    Clin Cardiol; 1985 Mar; 8(3):176-9. PubMed ID: 4038927
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Verapamil in the treatment of hypertrophic cardiomyopathy.
    Rosing DR; Epstein SE
    Ann Intern Med; 1982 May; 96(5):670-2. PubMed ID: 6122414
    [No Abstract]   [Full Text] [Related]  

  • 63. Effects of nifedipine, verapamil and diltiazem on serum biochemical parameters and aortic composition of atherosclerotic chickens.
    García-Pérez B; Ayala I; Castells MT; Doménech G; Sánchez-Polo MT; García-Partida P; Valdés M
    Biomed Pharmacother; 2005; 59(1-2):1-7. PubMed ID: 15740928
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Calcium-channel blockers and systemic hypertension.
    Frishman WH; Charlap S; Ocken S; Spivack C
    J Clin Hypertens; 1985 Jun; 1(2):107-22. PubMed ID: 3915318
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Treatment of angina pectoris with calcium antagonists].
    Hopf R; Becker HJ; Kober G; Dowinsky S; Kaltenbach M
    Herz; 1982 Aug; 7(4):221-34. PubMed ID: 6751971
    [No Abstract]   [Full Text] [Related]  

  • 66. [Treatment of circulatory diseases: recent progress. 4. Cardiomyopathies].
    Kawamura K
    Nihon Naika Gakkai Zasshi; 1986 Jul; 75(7):873-80. PubMed ID: 2878052
    [No Abstract]   [Full Text] [Related]  

  • 67. Calcium channel blockers in primary pulmonary hypertension.
    Rubin LJ
    Chest; 1985 Oct; 88(4 Suppl):257S-260S. PubMed ID: 4042732
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The potential synergistic effect of calcium channel blockers and alpha-tocopherol on gastric mucosal injury induced by ischaemia-reperfusion.
    al-Dohayan AD; al-Tuwaijri AS
    Eur J Gastroenterol Hepatol; 1996 Nov; 8(11):1107-10. PubMed ID: 8944374
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Calcium channel blocking drugs. Part II: Clinical applications.
    Brill DM; Fozzard HA
    Compr Ther; 1985 Oct; 11(10):67-71. PubMed ID: 2414054
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Secondary prevention with calcium channel-blocking drugs in patients after myocardial infarction: a critical review.
    Moss AJ
    Circulation; 1987 Jun; 75(6 Pt 2):V148-53. PubMed ID: 3552311
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Calcium channel blockers in the management of arterial hypertension.
    Thomas T; Vidt DG
    Cleve Clin J Med; 1987; 54(6):529-36. PubMed ID: 3319284
    [No Abstract]   [Full Text] [Related]  

  • 72. Hypertrophic cardiomyopathy--therapy with slow channel inhibiting agents.
    Chatterjee K; Raff G; Anderson D; Parmley WW
    Prog Cardiovasc Dis; 1982; 25(3):193-210. PubMed ID: 6216500
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Calcium antagonists and chronic cardiac failure.
    Kendall MJ; Horton RC; Smith SR
    Postgrad Med J; 1986 Aug; 62(730):713-7. PubMed ID: 3534840
    [No Abstract]   [Full Text] [Related]  

  • 74. Evidence for or against the efficacy of calcium channel blockers for management of hypertrophic cardiomyopathy in cats.
    Bright JM; Golden AL
    Vet Clin North Am Small Anim Pract; 1991 Sep; 21(5):1023-34. PubMed ID: 1683045
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Calcium antagonists and glycaemic control.
    Kendall MJ; Horton RC; Chellingsworth MC
    J Clin Hosp Pharm; 1986 Jun; 11(3):175-80. PubMed ID: 3528228
    [No Abstract]   [Full Text] [Related]  

  • 76. Phaeochromocytoma and hypertrophic cardiomyopathy: apparent suppression of symptoms and noradrenaline secretion by calcium-channel blockade.
    Serfas D; Shoback DM; Lorell BH
    Lancet; 1983 Sep; 2(8352):711-3. PubMed ID: 6136843
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Why should cardiologists consider genetic testing for hypertrophic cardiomyopathy?
    Judge DP
    JACC Heart Fail; 2015 Feb; 3(2):189-91. PubMed ID: 25543975
    [No Abstract]   [Full Text] [Related]  

  • 78. New perspectives in the pharmacological treatment of hypertrophic cardiomyopathy.
    Maltês S; Lopes LR
    Rev Port Cardiol (Engl Ed); 2020 Feb; 39(2):99-109. PubMed ID: 32245685
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Long-term therapy with trimetazidine in cardiomyopathic Syrian hamster BIO 14:6.
    D'hahan N; Taouil K; Dassouli A; Morel JE
    Eur J Pharmacol; 1997 Jun; 328(2-3):163-74. PubMed ID: 9218698
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Effect of calcium antagonist on reactive hypoglycemia].
    Sanke T
    Nihon Shokakibyo Gakkai Zasshi; 1984 Jan; 81(1):121. PubMed ID: 6748291
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.